~~<i id='8576040B89'><strike id='8576040B89'><tt id='8576040B89'><pre id='8576040B89'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：comprehensive 2025-09-29 07:35:56 Page View：1485

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing
Next article： Apple is now the first public company to be valued at $3 trillion

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

My superpower is killing ticks

EssayauthorRichardS.Ostfeldhasdevelopedanimmunitythatkillstickswhentheytrytobitehim.CDCSometimespeop